Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.

Juratli TA, Jones PS, Wang N, Subramanian M, Aylwin SJB, Odia Y, Rostami E, Gudjonsson O, Shaw BL, Cahill DP, Galanis E, Barker FG 2nd, Santagata S, Brastianos PK.

Cancer. 2019 Sep 1;125(17):2910-2914. doi: 10.1002/cncr.32197. Epub 2019 Jul 17. No abstract available.

PMID:
31314136
2.

A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly.

Trainer PJ, Newell-Price JDC, Ayuk J, Aylwin SJB, Rees A, Drake W, Chanson P, Brue T, Webb SM, Fajardo C, Aller J, McCormack AI, Torpy DJ, Tachas G, Atley L, Ryder D, Bidlingmaier M.

Eur J Endocrinol. 2018 Aug;179(2):97-108. doi: 10.1530/EJE-18-0138. Epub 2018 May 22.

3.

Visceral Adiposity Is an Independent Determinant of Hypercoagulability as Measured by Thrombin Generation in Morbid Obesity.

Chitongo PB, Roberts LN, Yang L, Patel RK, Lyall R, Luxton R, Aylwin SJB, Arya R.

TH Open. 2017 Dec 15;1(2):e146-e154. doi: 10.1055/s-0037-1608942. eCollection 2017 Jul.

4.

Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI.

Koulouri O, Kandasamy N, Hoole AC, Gillett D, Heard S, Powlson AS, O'Donovan DG, Annamalai AK, Simpson HL, Akker SA, Aylwin SJ, Brooke A, Buch H, Levy MJ, Martin N, Morris D, Parkinson C, Tysome JR, Santarius T, Donnelly N, Buscombe J, Boros I, Smith R, Aigbirhio F, Antoun NM, Burnet NG, Cheow H, Mannion RJ, Pickard JD, Gurnell M.

Eur J Endocrinol. 2016 Nov;175(5):485-498. Epub 2016 Aug 25.

5.

Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor.

Aylwin SJ, Bodi I, Beaney R.

Pituitary. 2016 Oct;19(5):544-6. doi: 10.1007/s11102-015-0663-4. No abstract available.

6.

Disease severity and staging of obesity: a rational approach to patient selection.

Whyte MB, Velusamy S, Aylwin SJ.

Curr Atheroscler Rep. 2014 Nov;16(11):456. doi: 10.1007/s11883-014-0456-7. Review.

PMID:
25278281
7.

Importance of cannulated prolactin test in the definition of hyperprolactinaemia.

Whyte MB, Pramodh S, Srikugan L, Gilbert JA, Miell JP, Sherwood RA, McGregor AM, Aylwin SJ.

Pituitary. 2015 Jun;18(3):319-25. doi: 10.1007/s11102-014-0576-7.

PMID:
24879500
8.

Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes.

Huda MS, Amiel SA, Ross P, Aylwin SJ.

Diabetes Care. 2014;37(5):e87-8. doi: 10.2337/dc13-2132. No abstract available.

PMID:
24757248
9.

High prevalence of vitamin D insufficiency in a United Kingdom urban morbidly obese population: implications for testing and treatment.

Grace C, Vincent R, Aylwin SJ.

Surg Obes Relat Dis. 2014 Mar-Apr;10(2):355-60. doi: 10.1016/j.soard.2013.07.017. Epub 2013 Aug 29.

PMID:
24411192
10.

Phaeochromocytoma [corrected] crisis.

Whitelaw BC, Prague JK, Mustafa OG, Schulte KM, Hopkins PA, Gilbert JA, McGregor AM, Aylwin SJ.

Clin Endocrinol (Oxf). 2014 Jan;80(1):13-22. doi: 10.1111/cen.12324. Epub 2013 Oct 17. Erratum in: Clin Endocrinol (Oxf). 2013 Mar;80(3):468.

PMID:
24102156
11.

Effects of mitotane treatment on human steroid metabolism: implications for patient management.

Ghataore L, Chakraborti I, Aylwin SJ, Schulte KM, Dworakowska D, Coskeran P, Taylor NF.

Endocr Connect. 2012 Jul 21;1(1):37-47. doi: 10.1530/EC-12-0028. Print 2012 Jul 1.

12.

Necessity for long-term follow-up of patients with head and neck paraganglioma and mutation in the succinate dehydrogenase genes: an index case report and literature review.

Samji KB, Crown AL, Buxton-Thomas MS, Aylwin SJ, Schulte KM, Dizdarevic S.

Endocr Pract. 2012 Sep-Oct;18(5):e130-4. doi: 10.4158/EP11184.CR. Review.

PMID:
22982783
13.

GLP-1 and glucagon secretion from a pancreatic neuroendocrine tumor causing diabetes and hyperinsulinemic hypoglycemia.

Roberts RE, Zhao M, Whitelaw BC, Ramage J, Diaz-Cano S, le Roux CW, Quaglia A, Huang GC, Aylwin SJ.

J Clin Endocrinol Metab. 2012 Sep;97(9):3039-45. doi: 10.1210/jc.2011-2005. Epub 2012 Jul 6.

PMID:
22774207
14.

Temozolomide in the management of dopamine agonist-resistant prolactinomas.

Whitelaw BC, Dworakowska D, Thomas NW, Barazi S, Riordan-Eva P, King AP, Hampton T, Landau DB, Lipscomb D, Buchanan CR, Gilbert JA, Aylwin SJ.

Clin Endocrinol (Oxf). 2012 Jun;76(6):877-86. doi: 10.1111/j.1365-2265.2012.04373.x. Review.

PMID:
22372583
15.

Assessment of obesity beyond body mass index to determine benefit of treatment.

Aasheim ET, Aylwin SJ, Radhakrishnan ST, Sood AS, Jovanovic A, Olbers T, le Roux CW.

Clin Obes. 2011 Apr;1(2-3):77-84. doi: 10.1111/j.1758-8111.2011.00017.x. Epub 2011 Jul 5.

PMID:
25585572
16.

Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation.

le Roux CW, Borg C, Wallis K, Vincent RP, Bueter M, Goodlad R, Ghatei MA, Patel A, Bloom SR, Aylwin SJ.

Ann Surg. 2010 Jul;252(1):50-6. doi: 10.1097/SLA.0b013e3181d3d21f.

PMID:
20562614
17.

Visceral adiposity is closely correlated with neck circumference and represents a significant indicator of insulin resistance in WHO grade III obesity.

Yang L, Samarasinghe YP, Kane P, Amiel SA, Aylwin SJ.

Clin Endocrinol (Oxf). 2010 Aug;73(2):197-200. doi: 10.1111/j.1365-2265.2009.03772.x. Epub 2009 Dec 29.

PMID:
20050862
18.

When the brakes came off: re-feeding oedema after deflation of a gastric band: a case report.

Vincent RP, Aylwin SJ, le Roux CW.

Obes Surg. 2009 Oct;19(10):1468-70. doi: 10.1007/s11695-009-9935-2. Epub 2009 Aug 13.

PMID:
19680731
19.

Evolution of gonadotropin deficiency in a patient with type II autosomal dominant GH deficiency.

Turton JP, Buchanan CR, Robinson IC, Aylwin SJ, Dattani MT.

Eur J Endocrinol. 2006 Dec;155(6):793-9.

PMID:
17132747
20.

Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety.

Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJ.

Br J Surg. 2006 Feb;93(2):210-5.

PMID:
16392104
21.

Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters.

le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG, Bloom SR.

Ann Surg. 2006 Jan;243(1):108-14.

22.

Attenuated peptide YY release in obese subjects is associated with reduced satiety.

le Roux CW, Batterham RL, Aylwin SJ, Patterson M, Borg CM, Wynne KJ, Kent A, Vincent RP, Gardiner J, Ghatei MA, Bloom SR.

Endocrinology. 2006 Jan;147(1):3-8. Epub 2005 Sep 15.

PMID:
16166213
23.

The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.

Gilbert JA, Miell JP, Chambers SM, McGregor AM, Aylwin SJ.

Clin Endocrinol (Oxf). 2005 Jun;62(6):742-7.

PMID:
15943838
24.

FSH secretion predominates in vivo and in vitro in patients with non-functioning pituitary adenomas.

Hanson PL, Aylwin SJ, Monson JP, Burrin JM.

Eur J Endocrinol. 2005 Mar;152(3):363-70.

PMID:
15757852
25.
26.

The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas.

Hunter JA, Skelly RH, Aylwin SJ, Geddes JF, Evanson J, Besser GM, Monson JP, Burrin JM.

Eur J Endocrinol. 2003 Feb;148(2):203-11.

PMID:
12590639
27.

The relationship between steroidogenic factor 1 and DAX-1 expression and in vitro gonadotropin secretion in human pituitary adenomas.

Aylwin SJ, Welch JP, Davey CL, Geddes JF, Wood DF, Besser GM, Grossman AB, Monson JP, Burrin JM.

J Clin Endocrinol Metab. 2001 Jun;86(6):2476-83.

PMID:
11397843
28.

Expression and secretion of neural cell adhesion molecules by human pituitary adenomas.

De Jong I, Aylwin SJ, Olabiran Y, Geddes JF, Monson JP, Wood DF, Burrin JM.

Ann Clin Biochem. 1999 Sep;36 ( Pt 5):660-5.

PMID:
10505219
29.

Steroidogenic factor 1-DNA binding: a kinetic analysis using surface plasmon resonance.

Bryan D, Aylwin SJ, Newman DJ, Burrin JM.

J Mol Endocrinol. 1999 Jun;22(3):241-9.

PMID:
10343283
30.

Free alpha-subunit and intact TSH secretion in vitro are closely associated in human somatotroph adenomas.

Aylwin SJ, King A, Blenke A, Geddes JF, Wood DF, Monson JP, Burrin JM.

Eur J Endocrinol. 1998 Oct;139(4):378-86.

PMID:
9820613
31.

Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.

Korbonits M, Jacobs RA, Aylwin SJ, Burrin JM, Dahia PL, Monson JP, Honegger J, Fahlbush R, Trainer PJ, Chew SL, Besser GM, Grossman AB.

J Clin Endocrinol Metab. 1998 Oct;83(10):3624-30.

PMID:
9768675
32.
33.

Calcium and glycoprotein hormone alpha-subunit gene expression and secretion in alpha T3-1 gonadotropes.

Holdstock JG, Aylwin SJ, Burrin JM.

Mol Endocrinol. 1996 Nov;10(11):1308-17.

PMID:
8923457
34.

The role of transcription factors in the pituitary expression of the glycoprotein hormone alpha-subunit gene.

Aylwin SJ, Burrin JM.

J Mol Endocrinol. 1995 Dec;15(3):221-31. Review. No abstract available.

PMID:
8748128
35.

Glycoprotein hormone alpha-subunit production and plurihormonality in human corticotroph tumours--an in vitro and immunohistochemical study.

Desai B, Burrin JM, Nott CA, Geddes JF, Lamb EJ, Aylwin SJ, Wood DF, Thakkar C, Monson JP.

Eur J Endocrinol. 1995 Jul;133(1):25-32.

PMID:
7542980
36.

Effects of pituitary adenylate cyclase-activating polypeptide on hormone secretion by human pituitary adenomas in vitro.

Desai BJ, Monson JP, Holdstock JG, Aylwin SJ, Geddes JF, Wood DF, Burrin JM.

J Clin Endocrinol Metab. 1994 Dec;79(6):1771-7.

PMID:
7527412
37.

Catalytic converter and suicide risk.

Wagg AS, Aylwin SJ.

Lancet. 1993 Nov 20;342(8882):1295. No abstract available.

PMID:
7694022

Supplemental Content

Loading ...
Support Center